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Abstract: Vascular endothelial growth factors (VEGFs) are the family of extracellular signaling
proteins involved in the processes of angiogenesis. VEGFA overexpression and altered regulation of
VEGFA signaling pathways lead to pathological angiogenesis, which contributes to the progression
of various diseases, such as age-related macular degeneration and cancer. Monoclonal antibodies and
decoy receptors have been extensively used in the anti-angiogenic therapies for the neutralization of
VEGFA. However, multiple side effects, solubility and aggregation issues, and the involvement of
compensatory VEGFA-independent pro-angiogenic mechanisms limit the use of the existing VEGFA
inhibitors. Short chemically synthesized VEGFA binding peptides are a promising alternative to
these full-length proteins. In this review, we summarize anti-VEGFA peptides identified so far and
discuss the molecular basis of their inhibitory activity to highlight their pharmacological potential as
anti-angiogenic drugs.
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1. Introduction
The enhancement of the efficiency, selectivity, and targeting of the pharmaceuticals to
the desired biomolecules and cells is one of the main objectives of modern drug design.
Despite progress in the understanding of molecular mechanisms of various diseases, many
challenges remain in the development of minimally invasive therapies with optimal drug
dosing and duration. In particular, this refers to the disorders that involve the blood
vessels growth that is normally tuned by the equilibrium between pro- and anti-angiogenic
factors [1,2]. Since the recognition of the fundamental role of vascular endothelial growth
factors (VEGFs) in vasculogenesis and angiogenesis, many efforts have been devoted to
the design of molecules that modulate VEGF-dependent signaling pathways by controlling
active VEGF concentration. This therapeutic intervention is particularly important for the
treatment of ischemic and inflammatory disorders, age-related macular degeneration, pso-
riasis, and cancer, where false regulation of VEGF signaling contributes to the progression
of the disease [3–5].
Vascular endothelial growth factors are expressed as numerous splice isoforms of
VEGFA, VEGFB, VEGFC, VEGFD, and placenta growth factor (PlGF). Two more VEGFs
are produced by zoonotic parapoxvirus (VEGFE) and some species of snakes (VEGFF) [6].
This structural versatility affords multiple signaling outcomes even with the same VEGF
receptor [7]. VEGFA is a key mediator of angiogenesis. The alternative splicing of the
VEGFA gene is affected by hypoxia, shear stress, oncogenes, and tumor suppressor genes,
thereby leading to the production of various VEGFA isoforms of different lengths, in-
cluding VEGFA111, VEGFA121, VEGFA165, VEGFA189, VEGFA206, and VEGFAx [7]. In
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physiological conditions, the active VEGF exists as a dimer with two receptor binding sites
with glycosylated monomers bound by disulfide bonds in the antiparallel way [8].
Several VEGF receptors have been identified, including VEGFR1, VEGFR2, and
VEGFR3. The VEGFR1 and VEGFR2 regulate physiological angiogenesis and vascular
permeability, whereas the VEGFR3 drives lymphangiogenesis mediated by VEGFC/D [9].
The VEGFR2, which is expressed in vascular endothelial cells, is the main receptor for
angiogenic actions of VEGFA, VEGFC, VEGFD, and VEGFE. It is a member of the tyrosine
kinase superfamily and is composed of an extracellular part with seven immunoglobulin-
like domains (D1-7), a single transmembrane region (TMD), a juxtamembrane domain
(JMD), a split tyrosine kinase domain (TKD), and a C-terminal tail (Figure 1) [10,11].
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Figure 1. (A) Diagram of the VEGFR2 structure. VEGFR2 is composed of an extracellular domain
(ECD) with seven Ig-like subdomains (D1-7), a transmembrane domain (TMD), a juxtamembrane
domain (JMD), a catalytic tyrosine kinase domain (TKD) including ATP binding domain (TKD1),
kinase insert domain (KID) and phosphotransferase domain (TKD2), and a flexible C-terminal
domain (CTD). (B) VEGFA-activated VEGFR2 homodimer. VEGFA binding to VEGFR2 results in the
phosphorylation of several tyrosine residues in TKD. (C) Molecular structure of VEGFA binding to
D2 and D3 of VEGFR2 (PDB ID: 3V2A). (D) Molecular structure of TKD of VEGFR2 including TKD1
(N-lobe), KID, and T 2 (C-lobe) (PDB ID: 4ASD) Adapted from [11], F ntiers, 2020.
The interaction of the receptor with VEGFs leads to the receptor dimerization and
phosphorylation of specific tyrosine residues of the intracellular region followed by ac-
tivation of downstream signaling pathways, which involve various signaling molecules
and affect cell migration, organization, proliferation, and differentiation. In addition to
VEGFRs, VEGFs bind to neuropilin co-receptors NRP1 and NRP2 and glycosaminoglycans,
such as heparin, syndecans, and perlecans, thereby modulating the biological output of
VEGF-mediated signaling [12–14].
VEGFA is the most studied growth factor of the VEGF family. Several strategies have
been developed for targeting VEGFA signaling pathways for the treatment of angiogenesis-
dependent diseases. These approaches include inhibition of the VEGFA secretion, neu-
tralization of VEGFA with aptamers, antibodies, soluble VEGFRs, and the use of small-
molecule inhibitors of VEGFA–VEGFR interaction or inhibitors of the tyrosine kinase
activity of the receptor [15,16]. In principle, the inhibition of VEGFA–VEGFR interaction
may be achieved with (i) a molecule that interacts with the receptor-binding domain of
VEGFA or (ii) a molecule that binds to the recognition surface of the receptor. In this
case, the former mode of inhibition is preferable, because of the risk of affecting other
signaling pathways by blocking the interaction of the receptor with other natural ligands
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that are involved in processes other than angiogenesis [17–19]. In addition, extracellular
VEGFA can be blocked more easily than membrane-bound receptor since there is no need
to penetrate tissue to target it. Nevertheless, several VEGFR inhibitors are used in medicine,
such as ramucirumab for certain advanced cancers [20].
Among clinically approved anti-VEGFA drugs, antibodies (mAbs) and soluble recep-
tors (decoy receptors) are the most widely used, especially in ophthalmology. Bevacizumab
(Avastin®), a full-length mAb against VEGFA, initially approved for the treatment of
advanced carcinomas, has been used extensively also for age-related macular degener-
ation (AMD) and other chorioretinal vascular disorders [21,22]. Monoclonal antibody
ranibizumab (Lucentis®), which binds all isoforms of VEGFA, was designed specifically
to treat neovascular AMD [23,24]. High-affinity brolucizumab (Beovu®) is a recently
approved anti-VEGFA single-chain antibody fragment for the treatment of neovascular
AMD [25]. Many attempts were made to design VEGFA inhibitors based only on the
binding domains of the VEGFR. In this way, several VEGF-traps were developed, includ-
ing aflibercept (Eylea® and Zaltrap®), which consists of the second Ig-like domain of
VEGFR1 and the third domain VEGFR2, fused to the Fc portion of IgG1 [26,27]. Pegap-
tanib (Macugen®), a targeted anti-VEGFA aptamer developed by Eyetech Pharmaceuticals
and Pfizer, was approved by FDA for patients with choroidal neovascularization. An-
other VEGFR-derived chimerical protein conbercept (Lumitin®), which is—similar to
aflibercept—able to bind in addition to VEGFA also PlGF and VEGFB, was constructed by
fusing VEGFR1D2 and VEGFR2D3,D4 extracellular domains with the Fc region of a human
immunoglobulin IgG1 [28].
Despite all the achievements, many drawbacks of the existing VEGFA inhibitors limit
their use in anti-angiogenic therapy. The systemic application of anti-angiogenic drugs can
cause multiple side effects, such as vascular disorders in healthy organs or impaired wound
healing. The inhibition of VEGFA signaling may also lead to the development of resistance
to the therapy due to the involvement of compensatory VEGFA-independent pathways
of angiogenesis. The intravitreal injections of anti-VEGFA drugs for the retinal treatment
avoid systemic off-target effects, but repeated injections create a significant burden to the
patients and induce rare but serious adverse effects, such as ocular infections and retinal
detachment [29–31]. The design of novel VEGFA inhibitors and the development of the
technologies to improve their pharmacological profiles remain a high-priority research
area [32]. For example, the intravitreal half-life of the therapeutic antibodies and proteins
was extended 3–4 fold by conjugated hyaluronan-binding peptide [33]. Another approach
to avoid frequent injections of anti-VEGFA mAbs involved their delivery with sustained
release systems (e.g., lipid nanoparticles) [34].
2. Peptide-Based Therapeutics for VEGFA Binding
In addition to the current anti-VEGF proteins, interesting therapeutic opportunities
can be offered by VEGFR mimetic compounds and by glycosaminoglycan mimicking
peptides, which can sequester VEGFA from the extracellular environment. The design of
small peptide VEGFA inhibitors is a promising approach for the development of novel
pharmaceuticals with VEGFA binding properties. Peptides are a useful starting point
in the design of new pharmaceuticals for disruption of the protein–protein and protein–
carbohydrate interfaces, since they can be easily synthesized and modified to meet drug-like
requirements [35–37]. A high potential of peptide drugs resulted in the continuing growth
of their number entering the clinical phase, as well as an increase in the peptide market,
which is expected to reach $50B in 2025 [38].
Peptides have many advantages compared to many other small molecules. In general,
they are less toxic and do not accumulate in the body due to in vivo degradation by pro-
teases and efficient elimination. The half-life of the peptides can be easily increased by the
introduction of non-coded amino acids, acylation, pegylation, cyclization, or preparation
of peptidomimetics [39].
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In general, antibodies and Fab-fragments have higher binding affinity to the targets
compared to peptides. On the other hand, peptides can be used at higher molar con-
centrations than full-length antibodies and proteins, which have limitations because of
the high molecular weight, solubility and aggregation issues, and low-temperature stor-
age requirements [40–42]. Aggregation may lead to immunogenicity and loss of drug
activity in vivo, in particular at the sites where long retention at body temperature is
needed in therapy (e.g., ocular injections). From the formulation viewpoint, peptides can
be more easily incorporated into controlled drug delivery systems at adequate stability
and concentrations.
Furthermore, encapsulation or binding of the peptides to the biopolymeric support
can lead to sustained drug release and prolonged pharmacological action [43]. In this case,
the biomaterial composition, its degradation rate, and the mode of peptide attachment
play important roles. An interplay of various processes on the biomaterial surface can
take place. Possible mechanisms of up- and downregulation of growth factor signaling by
VEGFA binding biomaterials were discussed in detail by Belair et al. [44]. Allosteric VEGFA
sequestering by anti-VEGFA peptide or biomaterial, where the receptor-binding domain of
VEGFA is not involved, may enhance the pro-angiogenic effect since the growth factor is
still able to bind and activate the receptor. On the contrary, the sequestering via the active
site of the VEGFA molecule may increase or decrease angiogenic activity, depending on the
affinity of the VEGFA binding ligand. When the affinity is low, sequestering biomaterial
may simply enhance the residence time of the growth factor and locally enrich the cell
environment with VEGFA by releasing it and accelerating by that pro-angiogenic signaling.
On the contrary, the high affinity of the peptide ligand, which blocks the active site of
VEGFA, may favor the anti-angiogenic effect by preventing the interaction VEGFA–VEGFR.
Biomaterial degradation is also an important issue. When the peptide ligand is covalently
attached to a slowly degrading biopolymeric support, the normal VEGFA inactivation
by endocytosis of the VEGFA/peptide complex is prevented. Thus, instead of blocking
VEGFA signaling, it may promote angiogenesis by forming a local VEGFA depot with
following slow release of the growth factor (Figure 2). On the contrary, the fast degradation
of the biopolymer with anti-VEGFA peptide can ensure sequestering and elimination of
VEGFA from the extracellular matrix, resulting in an anti-angiogenic activity. Thus, careful
fine tuning of the structures of anti-VEGFA peptide and biopolymeric support is necessary
for reaching the desired drug actions.
Short peptides and peptidomimetics, as well as peptide-based biomaterials, which
can bind VEGFA with high affinity, are promising alternatives to the current full-length
monoclonal antibodies and soluble receptors. They can improve the existing strategies
for the treatment of VEGFA-dependent diseases in terms of the effectiveness, rational use
of the pharmaceuticals, and patient burden. To date, a number of peptide inhibitors of
VEGFA for various biomedical applications have been described. Herein, we summarize
the most interesting examples of anti-VEGFA peptides identified so far and highlight the
progress and perspectives in this field of drug research.
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2.1. Peptides as Glycosaminoglycan Mimics
Highly sulfated glycosaminoglycans (GAGs), in particular, eparin, heparan sulfate,
and chondroitin sulfate erivatives play important roles in the regulation of VEGF concen-
tration and serve as potent inhibitors of pathologic gr wth of blood v els [45–48]. The
binding to GAGs leads to the accumulation f th growth fact rs in proximity t the cell
surface, thus generating a growth factor reservoir. The int raction with GAGs can also
change the sig aling properties of VEGFs [49]. Neverth less, the function and influenc of
the ingle components a d the structural unit of these natural polymers on angiogenesis
are still unclear.
The most abundant sulfated glycosaminoglycan, heparin, typically consists of a repeat-
ing sulfated disaccharide unit (2-O-sulfoiduronic acid and 6-O-sulfo-N-sulfo-glucosamine).
The free sulfate groups of heparin are responsible for its negative charge and promote
electrostatic interaction with positively charged clusters of basic amino acids (arginine
and lysine) of the growth factors [50]. In addition, hydrogen bonding and hydrophobic
interactions also contribute to the binding [50]. The heparin-binding domain has been
identified in the C-terminal part of the VEGFA165 isoform of VEGFA [51]. Removal of
the last 55 amino acid residues does not significantly affect the VEGFA165 affinity to its
receptor, but leads to decreased bioactivity. The studies on modulation of angiogenesis by
VEGFA binding heparin-based oligosaccharides have shown promising results in vitro and
in vivo [52–56]. However, the inherent heterogeneity of heparin, caused by the different
molecular weights and sulfation patterns of polysaccharide chains, complicates the further
development of heparin-based pharmaceuticals. Therefore, the research was carried out to
determine minimal structural elements of heparin, which are necessary for VEGFA binding.
It was shown that the minimum size among the heparin oligosaccharides, which were able
to bind VEGFA165, was an octasaccharide. Tetradecasaccharide was able to bind VEGFA165
with an affinity comparable to that of heparin (Figure 3) [57].
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Figure 3. Binding model of the complex between heparin octasaccharide and heparin-binding
domain of VEGFA165 Adapted with permission from [53], American Chemical Society, 2013.
Due to the structural similarity, short eptides can mimic and substitute lecules
or their f agments in various biomedical applications. In particular, this refe s to the pep-
tides with the same functional groups as those pr sent in GAGs, namely, sulfate, c rboxyl,
and hydrox l functionali es (Tyr(SO3H), Asp, Glu, Ser, Thr r sidues). Short ulfated pep-
ides wi h Tyr(SO3H)-X-Tyr(SO3H) consensus sequences, where X is an arbitr ry amino
acid, were shown to mimic heparin-lik act vity (T ble 1) [58].
A combin torial approach d analysis of about 6600 tetrapeptides allowed th identi-
ficati n of the best binders with this pattern. Among them, Se -Tyr(SO3H) Asp-Tyr(SO3H)
showed 100 times stronger in eraction with VEGFA165 than heparin mimic suramin [59].
In erestingly, the peptide with this sequence and N- and C-terminal tetraglycines retained
the affinity to VEGFA165 without any significant anticoagulant effects. Ho ever, it was
also shown that the length of the peptide and variation in the positioning and number
of the sulfate groups can affect binding affinity. For exam le, the peptide with multiple
VEGFA165-binding domains was less active than a peptide with a single domain. Likewise,
an increasing number of sulfate groups had a negative effect on VEGFA165 affinity. Thus,
detailed structural characteristics of the peptides are extremely important for the tight
VEGFA binding, and the steric hindrance, unfavorable repulsion, or entropic factors have
to be taken into consideration in the design of small peptide heparin mimetics [59].
However, the formation of supramolecular structures on the base of heparin-like
VEGFA-binding peptides may favor angiogenesis instead of blocking it. Self-assembling
heparin-like peptide amphiphiles (PAs) were shown to mimic the functions of the natural
extracellular matrix to provide cell adhesion, proliferation, and differentiation [60,61].
These peptides formed a nanofibrous network and interacted with VEGFA with a binding
constant similar to that of heparin [62]. The study showed a burst release of the growth
factor from heparin and peptide amphiphile (PA) without the sulfonate group (Asp-PA)
over two hours, whereas the release rate was significantly lower for heparin-mimetic
PA (HM-PA) nanogel, which also promoted the formation of capillary-like structures of
HUVECs without exogenous VEGFA (Figure 4).
This peptide scaffold was able to entrap VEGFA to form a VEGFA depot and stimu-
lated the VEGFA signaling pathways more robustly than bare cell culture, probably, due
to the autocrine signaling [62,63]. More recently, a similar glycopeptide with sulfate, car-
boxyl, and hydroxyl functionalities was designed to bind multiple growth factors including
VEGFA165 [64]. In this case, highly sulfated monosaccharide was conjugated to the peptide
moiety via copper(I)-catalyzed alkyne–azide cycloaddition. This glycopeptide amphiphiles
self-assembled into nanoscale filaments due to the hydrophobic collapse of aliphatic tails
and β-sheet formation and exhibited a concentration-dependent multivalent interaction
with VEGFA165, which was even stronger than that of heparin. Due to the resemblance
to the heparin structure, this glycopeptide could mimic GAGs and promote angiogenesis.
Thus, despite a potent VEGF binding, the biological action of the heparin-like peptides de-
pends on their supramolecular organization and they can induce pro-angiogenic response
via autocrine signaling or due to the formation of VEGF reservoir, where VEGF is slowly
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released over time. This has to be taken into account in the design of VEGFA inhibitors on
the base of heparin peptide mimics.
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In vitro angiogenesis assay. Bright-field images of HUVECs cultured on heparin-mimetic PA nan-
ofiber matrix (A), Asp-PA nanofiber matrix (B), and bare tissue culture plate (C). Cell viability as-
say: heparin-mimetic PA nanofiber matrix (D), Asp-PA nanofiber matrix (E), and bare tissue cul-
ture plate (F) Adapted with permission from [62], American Chemical Society, 2011. 
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2.2. Peptides as VEGFR Mimics 
Very interesting therapeutic opportunities may be reached by the design of the short 
peptides that mimic the VEGFA-binding domains of the VEGFR. It was shown that the 
part of the receptor that encompasses N-terminal immunoglobulin-like extracellular 
ligand-binding domains (ECD) can bind VEGFA as effectively as the native receptor, and 
the domains 2 and 3 of VEGFR2 are necessary for the binding (Figure 1C) [11,65,66]. The 
101-amino acid peptide corresponding to the single domain 2 was synthesized by the 
solid-phase approach and it folded correctly after disulfide bridge formation. Neverthe-
less, the binding of the single D2 to VEGFA165, was 60–100 times weaker than that of the 
intact ECD [67]. 
The receptor-recognition site of VEGFA is large and topologically irregular with > 
800 Å2 of VEGFA surface binding to a single receptor [68]. The relatively shallow surfaces 
that form the VEGFA–VEGFR2 interface complicate the development of small molecules 
which are intended to target this interaction. In the very first studies, cellulose-bound 
and overlapping 13-mer peptide libraries with sequences derived from the third globular 
domain of VEGFR2 allowed the identification of the peptides that can bind to VEGFA165 
with high affinity. In particular, the fragment 247RTELNVGIDFNWEYPASK261 of the re-
ceptor (peptide Je-7) was found to inhibit microvascular endothelial cell (MVEC) prolif-
eration with IC50 of 0.1 μM (Table 2) [69]. 
Along with two highly conserved residues Trp258 and Pro261, Asp255 was shown to be 
a key residue for VEGFR2 binding and, probably, to contribute to the different binding 
modes of various VEGF receptors. The dimerized peptide Je-11 ([RTELNVGIDFN-
WEYPAS]2K) bound VEGFA165 with an IC50 of 0.5 μM. However, it inhibited MVECs 
proliferation with lower efficiency than the monomeric peptide because of the occupation 
of only one of the binding centers of VEGFA165 for steric reasons. Receptor autophos-
phorylation, cell proliferation, and migration assays showed that both peptides had an-
tagonistic activity only in the presence of exogenous VEGFA165. Further modifications of 
these peptides, including D-substitutions, resulted in increased serum stability and af-
finity to VEGFA165, leading to more potent inhibition of angiogenesis [70]. In particular, 
the best D,L-peptides blocked VEGFA165–VEGFR binding in the nanomolar range and 
inhibited the sprouting of capillary-like structures seven times better than the parent 
peptides. The structure of the branch strongly influenced the affinity of the dimers im-
mobilized on the hydrogel microspheres as a carrier [71]. The insertion of two additional 
lysines immediately before the branching point led to the removal of about 60% of 
VEGFA165 (Kd = 40 pM) from the solution in serum-free conditions. However, in the 
presence of the serum, a release of the bound growth factor from the carrier was acceler-
ated due to its interaction with multiple VEGFA-binding serum proteins, such as 
sVEGFR1, sVEGFR2, and α2-macroglobulin [72,73]. These peptide-based biomaterials 
were able to function in two different modes. They could downregulate VEGFA signal-
ing through growth factor sequestering or upregulate it via VEGFA binding and fol-
lowing sustained release. This approach was successfully used for the preparation of the 
biomaterials, which modulated VEGFA activity dynamically over time [74,75]. The pep-
tides were attached to PEG hydrogel microspheres with different degradation rates. 
Rapidly degrading microspheres reduced VEGFR2 activation in vitro and neovasculari-
zation in vivo, while microspheres with no inherent degradability functioned as a 
VEGFA depot by entrapping growth factor, and promoted its activity in the cell culture. 
Analysis of peptide libraries allowed identification of a series of arginine-rich hex-
apeptides, which inhibited VEGFA165 binding to VEGFR with IC50 up to 2 μM (RRKRRR) 
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2.2. Peptides as VEGFR Mimics
Very interesting therapeutic opportunities may be reached by the design of the short
peptides that mimic the VEGFA-binding domains of the VEGFR. It was shown that the part
of the receptor that encompasses N-terminal immunoglobulin-like extracellular ligand-
binding domains (ECD) can bind VEGFA as effectively as the native receptor, and the
domains 2 and 3 of VEGFR2 are necessary for the binding (Figure 1C) [11,65,66]. The
101-amino acid peptide corresponding to the single domain 2 was synthesized by the
solid-phase approach and it folded correctly after disulfide bridge formation. Nevertheless,
the binding of the single D2 to VEGFA165, was 60–100 times weaker than that of the intact
ECD [67].
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The receptor-recognition site of VEGFA is large and topologically irregular with
>800 Å2 of VEGFA surface binding to a single receptor [68]. The relatively shallow surfaces
that form the VEGFA–VEGFR2 interface complicate the development of small molecules
which are intended to target this interaction. In the very first studies, cellulose-bound and
overlapping 13-mer peptide libraries with sequences derived from the third globular do-
main of VEGFR2 allowed the identification of the peptides that can bind to VEGFA165 with
high affinity. In particular, the fragment 247RTELNVGIDFNWEYPASK261 of the receptor
(peptide Je-7) was found to inhibit microvascular endothelial cell (MVEC) proliferation
with IC50 of 0.1 µM (Table 2) [69].
Along with two highly conserved residues Trp258 and Pro261, Asp255 was shown to be a
key residue for VEGFR2 binding and, probably, to contribute to the different binding modes
of various VEGF receptors. The dimerized peptide Je-11 ([RTELNVGIDFNWEYPAS]2K)
bound VEGFA165 with an IC50 of 0.5 µM. However, it inhibited MVECs proliferation with
lower efficiency than the monomeric peptide because of the occupation of only one of
the binding centers of VEGFA165 for steric reasons. Receptor autophosphorylation, cell
proliferation, and migration assays showed that both peptides had antagonistic activity
only in the presence of exogenous VEGFA165. Further modifications of these peptides,
including D-substitutions, resulted in increased serum stability and affinity to VEGFA165,
leading to more potent inhibition of angiogenesis [70]. In particular, the best D,L-peptides
blocked VEGFA165–VEGFR binding in the nanomolar range and inhibited the sprouting of
capillary-like structures seven times better than the parent peptides. The structure of the
branch strongly influenced the affinity of the dimers immobilized on the hydrogel micro-
spheres as a carrier [71]. The insertion of two additional lysines immediately before the
branching point led to the removal of about 60% of VEGFA165 (Kd = 40 pM) from the solu-
tion in serum-free conditions. However, in the presence of the serum, a release of the bound
growth factor from the carrier was accelerated due to its interaction with multiple VEGFA-
binding serum proteins, such as sVEGFR1, sVEGFR2, and α2-macroglobulin [72,73]. These
peptide-based biomaterials were able to function in two different modes. They could
downregulate VEGFA signaling through growth factor sequestering or upregulate it via
VEGFA binding and following sustained release. This approach was successfully used for
the preparation of the biomaterials, which modulated VEGFA activity dynamically over
time [74,75]. The peptides were attached to PEG hydrogel microspheres with different
degradation rates. Rapidly degrading microspheres reduced VEGFR2 activation in vitro
and neovascularization in vivo, while microspheres with no inherent degradability func-
tioned as a VEGFA depot by entrapping growth factor, and promoted its activity in the
cell culture.
Analysis of peptide libraries allowed identification of a series of arginine-rich hexapep-
tides, which inhibited VEGFA165 binding to VEGFR with IC50 up to 2 µM (RRKRRR) [76].
Hexaarginine showed weaker inhibitory activity (IC50 = to 3.8 µM), whereas hexalysine
was not active. RKKRKR had a weaker VEGFA165 binding (IC50 = to 3.4 µM) than RRKRRR,
thus confirming the importance of a specific amino acid sequence, rather than just a positive
charge of the peptide. In addition, it was shown that the arginine-rich peptides have the
same or overlapping binding domains on the VEGFA165 molecule, and the interaction
involves both ends of the VEGFA121 fragment. Interestingly, despite the positive charge,
the peptides showed only limited interaction with heparin at the physiological conditions
and did not prevent its interaction with VEGFA165. The arginine-rich peptide RRKRRR in-
hibited VEGFA165-induced neovascularization in rabbit cornea and prevented both growth
and metastases of human colon carcinoma cells, demonstrating a powerful anti-angiogenic
effect [74]. In combination with itraconazole, which altered the signaling pathway of VEGF
stimulation, RRKRRR was used for the preparation of the nanoparticles with multivalent
binding interactions with VEGFA165, thus enhancing their anti-angiogenic activity [77]. To
enhance the proteolytic stability of the peptide, all-D-derivative (rrkrrr) was prepared [78].
In that case, the half-life of the peptide in serum was increased up to 27 times. Interestingly,
the strong interaction with VEGFA165 and pharmacological activity were preserved in
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the rrkrrr peptide, even though it was not a clean retro-inverso peptide. On the contrary
to RRKRRR, the dimerization of this peptide resulted in more potent inhibition of en-
dothelial cell proliferation and migration, as well as in vivo growth of VEGF-secreting
colorectal cancer cells [79]. Another approach to improving the stability and bioactivity of
anti-angiogenic peptides was described by Chan et al. [80]. It was based on the design of
a non-toxic cyclic peptide framework, which combined two anti-angiogenic epitopes to
elicit their synergistic effect by targeting different angiogenesis pathways. Natural cyclic
disulfide-rich peptides with high thermal and enzymatic stability were chosen as templates
for the insertion of the anti-angiogenic peptide sequences, resulting in non-toxic and stable
molecules with nanomolar potency. In particular, in combination with β-turn-derived
peptide from somatostatin (YwKV), RRKRRR inhibited the proliferation of HUVEC and
NT-29 cell lines similarly or more efficiently than anti-angiogenic drugs cilengitide and
sunitinib. However, comparing to cilengitide and sunitinib was perhaps not a good choice
as both are not very good inhibitors of HUVEC proliferation [81].
To find peptides that specifically bind VEGFA165, a random 7-mer peptide library
was screened by biopanning [82]. Two peptides (WHKPFRF and WHLPFKC) were found
to bind VEGFA with micromolar affinity and to inhibit HUVEC proliferation in a dose-
dependent manner. Interestingly, their sequences did not present any homology with the
primary sequence of VEGFR and, probably, mimicked a discontinuous VEGFA-binding
site of the receptor with the amino acid residues brought to spatial proximity by receptor
folding.
Furthermore, the screening of anti-VEGFA peptides by the phage display method led
to the design of a series of compounds, which could bind VEGFA with high affinity and
selectivity. In particular, two classes of the peptides with two- or three-helix bundles were
identified after several routes of selection with the libraries against VEGFA8-109 [83]. The
resolution of the crystal structure showed their interaction with receptor-binding regions
of VEGFA8-109 located at the two poles of the homodimer (Figure 5) [84].




Figure 5. Cartoon representation of crystal structures of α-peptide Z-1-2 bound to VEGFA8–109 (PDB 
ID: 3S1K) (left) and α/β-VEGF-1 bound to VEGFA8–109 (right) Residues in α/β-VEGF-1 are colored 
by type of residue (yellow for α, green for α-aminoisobutyric acid (Aib), and orange for cyclic β). 
VEGFA8–109 is depicted as a gray surface Adapted with permission from [84], PNAS, 2015. 
The peptides bound VEGFA8-109 with IC50 values in the nanomolar range (Table 2), 
but shorter peptide (mini-Z) was rapidly cleared from the bloodstream via renal elimi-
nation. In contrast, 18F-labeled triple-helix Z-3B showed clinically relevant prolonged re-
tention in plasma and was successfully used as a probe to monitor VEGFA levels in the 
growing ovarian tumor model. Pharmacokinetic positron emission tomography images 
with this peptide were comparable with those obtained using anti-VEGF antibody B20. 
Further optimization of the pharmacokinetics of Z-domain peptides was achieved by 
chain shortening and iterative introduction of non-proteinogenic amino acids, in partic-
ular, β3-residues, cyclic β-residues, and α-aminoisobutyric acid (Aib) [68,84]. Additional 
stabilization of the secondary structure was ensured with the disulfide bond. Thus, a se-
ries of two-helix α/β peptides with enhanced proteolytic stability was obtained. The 
half-life for one of the most promising peptides α/β-VEGF-2 in the presence of proteinase 
K was increased up to 670 min. 
Another series of VEGFA-binding peptides identified by the phage display method 
was described by Fairbrother et al. [85]. In particular, IC50 values measured by SPR for 
two most promising peptides v107 (GGNEc[CDIARMWEWEC]FERL) and its analog 
v114 (VEPNc[CDIHVMWEWEC]FERL) were 0.70 and 0.22 μM, respectively. The struc-
ture of the complex VEGFA8-109-v104 was studied in detail by NMR [86]. It was shown 
that the peptide has a mixed turn-helix conformation with hydrophobic residues faced 
toward the VEGFA8-109 molecule, and it consists of a disordered N-terminus (residues 1–
4), a type-I turn at residues 6–9, an extended region from residues 9–12, and a C-terminal 
α-helix from residues 13–19. It interacts with the receptor-binding region of VEGFA, thus 
competing with the receptor for VEGFA binding (Figure 6). 
 
Figure 6. Comparison of the VEGFA8-109-v107 complex (left) and the VEGFA8-109-Flt-1D2 (VEG-
FA8-109-VEGFR-1D2) complex (right). The VEGFA8-109 ribbon is colored grey, while the v107 and 
Flt-1D2 (VEGFR-1D2) ribbons are colored green with the side-chains in contact with VEGFA shown 
in magenta Adapted with permission from [86], Elsevier, 2002. 
Figure 5. Cartoon representation of crystal structures of α-peptide Z-1-2 bound to VEGFA8–109 (PDB
ID: 3S1K) (left) and α/β-VEGF-1 bound to VEGFA8–109 (right) Residues in α/β-VEGF-1 are colored
by type of residue (yellow for α, green for α-aminois butyric acid (Aib), and orange for cyclic β).
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The peptides bound VEGFA8-109 with IC50 valu s in the nanomolar range (Table 2), but
shorter peptide (mini-Z) was rapidly cleared from the bloodstream via renal elimination.
In contrast, 18F-labeled triple-helix Z-3B showed clinically relevant prolonged retention
in plasma and was successfully used as a probe to moni or VEGFA l vels in the growing
ovarian tumor model. Pharmacokinetic positron emission tomography images with this
peptide were comparable with tho e obtain u ing anti-VEGF an ibody B20. Further opti-
mization f the phar acokinetics of Z-domai peptides was achieved by chain shortening
and iterative introduction of non-proteinogenic ami o acids, in particular, β3-residues,
cyclic β-residues, and α-aminoisobutyric acid (Aib) [68,84]. Additional stabilization of
the secondary structure was ensured with the disulfide bond. Thus, a series of two-helix
α/β peptides with enhanced proteolytic stability was obtained. The half-life for one of the
most promising peptides α/β-VEGF-2 in the presence of proteinase K was increased up to
670 min.
Another series of VEGFA-binding peptides identified by the phage display method
was described by Fairbrother et al. [85]. In particular, IC50 values measured by SPR for
Pharmaceutics 2021, 13, 1337 10 of 16
two most promising peptides v107 (GGNEc[CDIARMWEWEC]FERL) and its analog v114
(VEPNc[CDIHVMWEWEC]FERL) were 0.70 and 0.22 µM, respectively. The structure of
the complex VEGFA8-109-v104 was studied in detail by NMR [86]. It was shown that the
peptide has a mixed turn-helix conformation with hydrophobic residues faced toward the
VEGFA8-109 molecule, and it consists of a disordered N-terminus (residues 1–4), a type-I
turn at residues 6–9, an extended region from residues 9–12, and a C-terminal α-helix from
residues 13–19. It interacts with the receptor-binding region of VEGFA, thus competing
with the receptor for VEGFA binding (Figure 6).




Figure 5. Cartoon representation of crystal structures of α-peptide Z-1-2 bound to VEGFA8–109 (PDB 
ID: 3S1K) (left) and α/β-VEGF-1 bound to VEGFA8–109 (right) Residues in α/β-VEGF-1 are colored 
by type of residue (yellow for α, green for α-aminoisobutyric acid (Aib), and orange for cyclic β). 
VEGFA8–109 is depicted as a gray surface Adapted with permission from [84], PNAS, 2015. 
The peptides bound VEGFA8-109 with IC50 values in the nanomolar range (Table 2), 
but shorter peptide (mini-Z) was rapidly cleared from the bloodstream via renal elimi-
nation. In contrast, 18F-labeled triple-helix Z-3B showed clinically relevant prolonged re-
tention in plasma and was successfully used as a probe to monitor VEGFA levels in the 
growing ovarian tumor model. Pharmacokinetic positron emission tomography images 
with this peptide were comparable with those obtained using anti-VEGF antibody B20. 
Further optimization of the pharmacokinetics of Z-domain peptides was achieved by 
chain shortening and iterative introduction of non-proteinogenic amino acids, in partic-
ular, β3-residues, cyclic β-residues, and α-aminoisobutyric acid (Aib) [68,84]. Additional 
stabilization of the secondary structure was ensured with the disulfide bond. Thus, a se-
ries of two-helix α/β peptides with enhanced proteolytic stability was obtained. The 
half-life for one of the most promising peptides α/β-VEGF-2 in the presence of proteinase 
K was increased up to 670 min. 
Another series of VEGFA-binding peptides identified by the phage display method 
was described by Fairbrother et al. [85]. In particular, IC50 values measured by SPR for 
two most promising peptides v107 (GGNEc[CDIARMWEWEC]FERL) and its analog 
v114 (VEPNc[CDIHVMWEWEC]FERL) were 0.70 and 0.22 μM, respectively. The struc-
ture of the complex VEGFA8-109-v104 was studied in detail by NMR [86]. It was shown 
that the peptide has a mixed turn-helix conformation with hydrophobic residues faced 
toward the VEGFA8-109 molecule, and it consists of a disordered N-terminus (residues 1–
4), a type-I turn at residues 6–9, an extended region from residues 9–12, and a C-terminal 
α-helix from residues 13–19. It interacts with the receptor-binding region of VEGFA, thus 
competing with the receptor for VEGFA binding (Figure 6). 
 
Figure 6. Comparison of the VEGFA8-109-v107 complex (left) and the VEGFA8-109-Flt-1D2 (VEG-
FA8-109-VEGFR-1D2) complex (right). The VEGFA8-109 ribbon is colored grey, while the v107 and 
Flt-1D2 (VEGFR-1D2) ribbons are colored green with the side-chains in contact with VEGFA shown 
in magenta Adapted with permission from [86], Elsevier, 2002. 
Figure 6. Comparison of the VEGFA8-109-v107 complex (left) and the VEGFA8-109-Flt-1D2
(VEGFA8-109-VEGFR-1D2) complex (right). The VEGFA8-109 ribbon is colored grey, while the v107
and Flt-1D2 (VEGFR-1D2) ribbons are colored green with the side-chains in contact with VEGFA
shown in magenta Adapted with permission from [86], Elsevier, 2002.
Later, the analysis of peptide libraries showed that W(E/D)W(E/D) is a consensus
core motif and the peptides with this amino acid sequence can be considered as mimotopes
that mimic VEGFA binding regions of VEGFR [87,88]. The study of a series of short
cyclic D-peptides confirmed this finding and only c(D-Pro-Trp-Glu-D-Pro-Trp-Glu) bound
VEGF11-109 in the low-millimolar range [89]. The high potential of v107 and v114 as
VEGFA165-binding peptides was also proven in the design of the bioanalytical tools for
VEGFA165 detection and the screening of other compounds that associate with the receptor-
binding surface of the VEGFA dimer [90,91].
To improve the affinity and enzymatic stability of the peptide v114, several modifica-
tions were carried out. In particular, v114* (in which the methionine residue was replaced
by a norleucine residue) was able to bind VEGFA165 with a Ki of 60 nM. Alanine scans of
v107 and v114 and a “β-scan” of v114* were used to determine the positions of the amino
acids that are crucial for VEGFA165 binding and, thereafter, a series of peptidomimetics on
the base of v114* was prepared and investigated [92]. However, the introduction of vari-
ous modifications and peptide shortening did not increase VEGFA affinity and inhibition
properties, although the authors concluded that the reduction in conformational flexibility
or the introduction of fluorinated 16Phe could improve VEGFA binding properties [93].
The conformational constraint was achieved by the introduction into v114* of non-
coded α-tetrasubstituted amino acid Aib, which is known to stabilize the folded peptide
structures [94]. The insertion of Aib into the N-terminal tail or in position 12 of the amino
acid sequence improved the inhibition of VEGFA165-induced proliferation of HUVEC cells
from IC50 = 20 µM (v114*) up to IC50 = 4 µM. In addition, Aib modification increased
the enzymatic stability of the peptide. Interestingly, VN peptide with shortened N-tail
showed a stronger VEGFA165 binding than v114* and the peptide without N-terminal
residues. This may indicate the importance of the N-terminal tail for the stabilization of the
conformation necessary for VEGFA165-binding, despite the absence of direct interaction
with the VEGFA165 molecule.
Another improvement of the binding affinity of v114* to VEGFA165 was achieved by
using the protein catalyzed capture agent method (Figure 7) [95].
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alkaline phosphatase (AP)-conjugated secondary antibody. The hit beads are washed, stripped, and
reprobed with AP-conjugated streptavidin to detect products of the target-catalyzed in situ click
chemistry (III,IV). Methionine-specific CNBr cleavage and sequencing by MALDI-TOF/TOF yield
the sequences of biligand candidates. The biligand candidates are synthesized on a larger scale and
assayed to assess in vitro performance (affinity, selectivity, stability, etc.). Repeating the process once
yields triligands and twice results in tetraligands Adapted from [95], John Wiley & Sons, 2016.
In situ click chemistry on the VEGFA165 molecule of azide-modified v114* and a
D-peptide from the peptide library led to the formation of a biligand with a higher affinity
to VEGFA165 than that of the v114* and D-peptide alone. The iterative addition of the third
and fourth D-peptide to v114* yielded a further increase in VEGFA165 inhibition, which
was comparable to that of bevacizumab in the case of the tetraligand. Along with high
affinity, the peptides showed improved stability against proteases and slow clearance from
the peritoneal cavity after intraperitoneal injection. However, they were rapidly removed
from the bloodstream after intravenous administration.
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Table 2. Peptides as VEGFR mimics.
Seq. ID Sequence VEGF Binding Ref.
Je-7 RTELNVGIDFNWEYPASK IC50 = 0.1 µM (proliferation assay)
[69]
Je-11 (RTELNVGIDFNWEYPAS)2K IC50 = 0.5 µM (proliferation assay)
- EfaylIDFNWEYPASK IC50 = 1 µM (competition assay)
[70–75]
- (EfaylIDFNWEYPAS)2K IC50 = 0.03 µM (competition assay)
- RRKRRR IC50 = 10 µM(inhibition assay)
[76–80]
- rrkrrr IC50 = 10 µM(inhibition assay)
MCoAA-01 CGRKRRRGCRRDSDCGACICRYwKVCGSGSDGGV
IC50 = 10.83 ± 0.09 µM (inhibition assay,
HUVECs)IC50 = 40.12 ± 0.13 µM
(inhibition assay, NT-29)
WHK7 WHKPFRF IC50 ~ 0.5 mM (proliferation assay)
[82]
WHL7 WHLPFKC IC50 ~ 0.5 mM (proliferation assay)










KD = 55 nM (Bio-Layer Interferometry)
α/β-VEGF-1 VDNKFNKEXc[CNZRAIEUALDPNLNDQQFHUKIWZIIXDC]





Ki = 0.39 µM (competitive fluorescence
polarization assay)
21 KFNKEXc[CNZRAIEUALDPNLNDUQFHUKIWZIIXDC]where D, F = β3-residues, X, Z = cyclic β-residues and U = Aib
Ki = 0.15 µM
(competitive fluorescence polarization
assay)
v107 GGNEc[CDIARMWEWEC]FERL IC50 = 0.70 ± 0.06 µM (SPR)
[85]
v114 VEPNc[CDIHVMWEWEC]FERL IC50 = 0.22 µM (SPR)
v114* VEPNc[CDIHVnLWEWEC]FERL
Ki = 0.06 µM
(competitive fluorescence polarization
assay)
[92]- VXPXc[CDIHVnLWXWEC]FZRX Ki = 1.6 µM (competitive fluorescencepolarization assay)
- XEXNc[CDIHV
nLXEWXC]FZRX,
where X = β3-residues, Z = cyclic β-residue
Ki = 4.6 µM (competitive fluorescence
polarization assay)
Aib2 VAibPNc[CDIHVnLWEWEC]FERL EC50 = 10.0 ± 1.1 µM (proliferation assay)
[94]
Aib12 VEPNc[CDIHVnLWAibWEC]FERL EC50 = 3.5 ± 0.7 µM (proliferation assay)
kv114* KAibKKc[CDIHVnLWEWEC]FERL EC50 = 6.0 ± 0.4 µM (proliferation assay)
VN VNc[CDIHVnLWEWEC]FERL EC50 = 4.0 ± 0.5 µM(proliferation assay)
Bi-Lv X-VEPNCDIHVMWEWECFERL-Tz4-lfrew -
[95]
Tri-Lv X-VEPNCDIHVMWEWECFERL-Tz4-lfrew-Tz4-eeird EC50 = 2.6 ± 0.5 nM (ELISA)
Tetra-Lv
X-VEPNCDIHVMWEWECFERL-Tz4-lfrew-Tz4-eeird-Tz4-qfkyr
where X = biotin-PEG3 label
Az4 = L-azidolysine
EC50 = 0.74 ± 0.05 nM (ELISA)
3. Conclusions and Perspectives
The research carried out during recent decades has allowed peptides to be selected that
can interact with vascular endothelial growth factor A and to inhibit its angiogenic activity
with high efficiency. In this review, we summarized the most interesting examples of
VEGFA-binding peptides. These peptides can be divided into two groups, namely, heparin
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mimics and the peptides disrupting the interaction of VEGFA with its receptor. The
optimization of their structures resulted in potent peptide inhibitors and peptidomimetics
with a high affinity to VEGFA. The properties of these peptides were further improved
to ensure high enzymatic stability and to prolong drug retention in biological fluids.
Encapsulation or binding of the peptides to the biopolymeric support was shown to be a
promising approach to prolong the pharmacological action on VEGFA. Depending on the
design, either anti-angiogenic or pro-angiogenic efficacy may be tailored to such systems.
A careful design of the biomaterial and optimization of the mode of attachment of the
peptide ligand can ensure the desired anti-angiogenic outcome. Thus, peptide inhibitors of
VEGFA hold a great promise as alternatives to the currently used pharmaceuticals in many
medical indications.
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